

**Key Lab of Health Technology  
Assessment, National Health  
Commission (Fudan University)**

WHO Collaborating Centre for Health Technology  
Assessment and Management



# NEWSLETTER

April 2022 / Issue 1



## HIGHLIGHTS

- KLHTA has been re-designated as a WHO Collaborating Centre for Health Technology Assessment and Management.
- The “Health Technology Assessment” online course, produced by KLHTA/WHOCC, was launched on China’s largest online course platform for the 12th time.
- KLHTA/WHOCC participated in WHO webinar series on country pharmaceutical pricing policies.
- ISPOR and HTAi News


## KLHTA RE-DESIGNATED AS WHO COLLABORATING CENTRE FOR HEALTH TECHNOLOGY ASSESSMENT AND MANAGEMENT

In April 2022, the World Health Organization Regional Office for the Western Pacific has re-designated the Key Lab of Health Technology Assessment (KLHTA), National Health Commission of the People's Republic of China (Fudan University) as a Collaborating Centre for Health Technology Assessment and Management (WHOCC).

KLHTA/WHOCC, headed by Dr. Yingyao Chen, will support WHO to strengthen the regional network for improving access to medicines and other health technologies, focusing on the area of health technology assessment (HTA) and priority setting; develop and strengthen capacity for HTA at the national and/or regional level, particularly for developing countries in the Region; and generate and disseminate evidence, knowledge, and good practices around prioritization and/or selection of medicines and health technologies.

KLHTA's predecessor, the Medical Technology Assessment Research Center affiliated to Shanghai Medical University, was established in 1994 as China's first HTA agency. KLHTA is devoted to scientific research, education and training, consultation, exchanges, and collaboration in the field of HTA. The WHO Western Pacific Region first designated KLHTA as a WHO Collaborating Centre in 2007 and re-designated three times thereafter.

### KLHTA/WHOCC Milestones



## “HEALTH TECHNOLOGY ASSESSMENT” LAUNCHED ON CHINESE UNIVERSITY MOOC PLATFORM FOR THE 12TH TIME

KLHTA/WHOCC launched “[Health Technology Assessment](#)” on China’s largest Massive Open Online Courses (MOOC) platform, Chinese University MOOC, for the 12<sup>th</sup> time in February 2022. This online course attracted 484 health technology assessment technicians and students nationwide and has been certified as a national quality course. The total number of students who participated in the online course has been exceed to 10,000.



*Since the “Health Technology Assessment” online course was launched in 2017, 12,563 students have registered and participated.*

In the booming stage of China's HTA, HTA MOOC will improve the education and promotion of HTA theories and methods, deepen and strengthen the implementation of HTA, and increase the influence of China's HTA research. At the same time, it can stimulate the interest of more Chinese students to learn health technology assessment, and make enterprises and policy makers pay more attention to health technology assessment. Translate HTA research into policy and play its due role in protecting public health.



*The “Health Technology Assessment” online course has nine modules that cover the essential elements of HTA and is taught by eight faculty members at KLHTA/WHOCC and Fudan University.*



*The “Health Technology Assessment” online course has been certified as a national high quality course.*


## KLHTA PARTICIPATED IN WHO WEBINAR SERIES ON COUNTRY PHARMACEUTICAL PRICING POLICIES

In February 2022, Professor Chen Yingyao, director of the Key Laboratory of Health Technology Assessment of the National Health Commission, The theme of this online seminar was "What happened before, during and after the drug price negotiation?"

Dr. Yingyao Chen, the head of KLHTA/WHOCC, was invited to participate in a series of online seminars on drug pricing policies in different countries organized by the World Health Organization (WHO). The theme of this online seminar was *What went on before, during and after pharmaceutical price negotiations*. Dr. Yingyao Chen shared his stories about negotiating price to improve access to medicines in China in the webinar. Dr. Yingyao Chen shared the insights on how to use the arts and science of negotiation to bring various parties to a mutually acceptable middle ground. With the growing list of medicines with annual costs in the tens of thousands per patient, Dr. Yingyao Chen discussed with the other expert panellists to reflect on how it would change and dynamics of price negotiation in the series.



### History of China National Reimbursement Drug List (NRDL) Updates



Source: Desk Research

Credit: Chen YY (webinar presentation on 22 February 2022)

*The history of China National Reimbursement Drug List (NRDL) Updates presented by Dr. Yingyao Chen in WHO webinar series in February 2022*

Dr. Yingyao Chen specially introduced the development history of the China National Medical Insurance Drug List (NRDL) at the seminar, and pointed out that in the new round of drug bulk procurement in China, the average price reduction of 48% was achieved, and the government agencies sought the best interests for the Chinese patient group.

The successful holding of this WHO series of online seminars on drug pricing policies in different countries has deepened the international exchange and cooperation on drug price negotiations. On the basis of summing up the past and present experience of various countries, experts have made prospects for the future development trends of drug price negotiations.



## ISPOR AND HTAi NEWS

### CHEERS 2022 PUBLISHED

Don Husereau, Michael Drummond, Federico Augustovski and others published a paper titled "Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force" in the "Value Health" magazine in January 2022 ("Integrated Health Economic Assessment Reporting Standards (CHEERS) Interpretation and Interpretation 2022: Report of the ISPOR CHEERS II Good Practice Working Group", original link: <https://pubmed.ncbi.nlm.nih.gov/35031088/>) The article, which explains and elaborates the report presents the 28 items of the new edition of CHEERS 2022, which contains suggestions, explanations and examples for each item.



**ScienceDirect**

Contents lists available at [sciencedirect.com](https://www.sciencedirect.com)  
Journal homepage: [www.elsevier.com/locate/jval](https://www.elsevier.com/locate/jval)

#### ISPOR Report

### Consolidated Health Economic Evaluation Reporting Standards (CHEERS) 2022 Explanation and Elaboration: A Report of the ISPOR CHEERS II Good Practices Task Force



Don Husereau, BScPharm, MSc, Michael Drummond, MCom, DPhil, Federico Augustovski, MD, MSc, PhD, Esther de Bekker-Grob, MSc, PhD, Andrew H. Briggs, DPhil, Chris Carswell, BScPharm, MSc, Lisa Caulley, MD, MPH, Nathorn Chaiyakunapruk, PharmD, PhD, Dan Greenberg, PhD, Elizabeth Loder, MD, MPH, Josephine Mauskopf, PhD, C. Daniel Mullins, PhD, Stavros Petrou, MPhil, PhD, Raoh-Fang Pwu, PhD, Sophie Staniszevska, DPhil

#### ABSTRACT

Health economic evaluations are comparative analyses of alternative courses of action in terms of their costs and consequences. The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement, published in 2013, was created to ensure health economic evaluations are identifiable, interpretable, and useful for decision making. It was intended as guidance to help authors report accurately which health interventions were being compared and in what context, how the evaluation was undertaken, what the findings were, and other details that may aid readers and reviewers in interpretation and use of the study. The new CHEERS 2022 statement replaces the previous CHEERS reporting guidance. It reflects the need for guidance that can be more easily applied to all types of health economic evaluation, new methods and developments in the field, and the increased role of stakeholder involvement including patients and the public. It is also broadly applicable to any form of intervention intended to improve the health of individuals or the population, whether simple or complex, and without regard to context (such as healthcare, public health, education, and social care). This Explanation and Elaboration Report presents the new CHEERS 2022 28-item checklist with recommendations and explanation and examples for each item. The CHEERS 2022 statement is primarily intended for researchers reporting economic evaluations for peer-reviewed journals and the peer reviewers and editors assessing them for publication. Nevertheless, we anticipate familiarity with reporting requirements will be useful for analysts when planning studies. It may also be useful for health technology assessment bodies seeking guidance on reporting, given that there is an increasing emphasis on transparency in decision making.

**Keywords:** cost-benefit analysis, economic evaluation, guidelines, methods, microeconomic analysis, reporting, standards.

VALUE HEALTH. 2022; 25(1):10-31


The Consolidated Health Economic Evaluation Reporting Standards (CHEERS) statement, published in 2013, was created to ensure health economic evaluations are identifiable, interpretable, and useful for decision making. It was intended as guidance to help authors report accurately which health interventions were being compared and in what context, how the evaluation was undertaken, what the findings were, and other details that may aid readers and reviewers in interpretation and use of the study. The new CHEERS 2022 statement replaces the previous CHEERS reporting guidance. It reflects the need for guidance that can be more easily applied to all types of health economic evaluation, new methods and

developments in the field, and the increased role of stakeholder involvement including patients and the public. It is also broadly applicable to any form of intervention intended to improve the health of individuals or the population, whether simple or complex, and without regard to context (such as healthcare, public health, education, and social care).

The new CHEERS checklist contains 28 items with accompanying descriptions. Items and recommendations are subdivided into 7 main categories: (1) Title, (2) Abstract, (3) Introduction, (4) Methods, (5) Results, (6) Discussion, and (7) Other Relevant Information. Compared with the CHEERS statement in 2013, the main changes in its content include: (1) Added items related to the participation and participation of patients or service recipients, the public, and communities or stakeholders. (2) The scope of the presentation has been expanded to make CHEERS more widely applicable to cost-benefit/benefit-cost analysis, as well as equity or distributional cost-benefit. (3) Added items related to reporting and usability of the Health Economic Analysis Program. (4) Items related to describing distribution effects have been added. (5) The item distinguishing between model-based and research-based measures was removed. (6) Added suggestions for reporting where to find publicly available models. Sharing unlocked models with editors and reviewers is encouraged.

## TOP 10 HEOR TRENDS

January 18, 2022, ISPOR published the “2022–2023 ISPOR Top 10 HEOR Trends” report. This is the fourth publication of the report. The report is based on input from its members and strategic curation from its Health Science Policy Council. The report identified ten trends in health economics and outcomes research for 2022–2023, including: (0) Pandemic (1) Real-World Evidence. (2) Value Assessment. (3) Health Equity. (4) Healthcare Financing. (5) Patient Engagement. (6) Drug and Healthcare Pricing. (7) Public Health. (8) Health Technology Assessment. (9) Health Data. (10) Artificial Intelligence



## TOP 10 HEOR TRENDS

March 8, 2022, ISPOR and the Bristol Myers Squibb-Pfizer Alliance, announced the launch of the "About Real-World Evidence " microsite. Real-world data (RWD) and real-world evidence (RWE) can be used to supplement randomized controlled trials (RCTs) and may help support clinical decision making.

([https://www.ispor.org/strategic-initiatives/real-world-evidence/about-real-world-evidence?utm\\_medium=press\\_release&utm\\_source=public&utm\\_campaign=general\\_ispor&utm\\_content=about+rwe\\_mar08](https://www.ispor.org/strategic-initiatives/real-world-evidence/about-real-world-evidence?utm_medium=press_release&utm_source=public&utm_campaign=general_ispor&utm_content=about+rwe_mar08))



## HTAi NEWS

The nomination and election of the committee of the International Health Technology Assessment Association (HTAi) in 2022 will be open from February 2 to February 18 for a three-year term (2022-2025). The HTAi Board seeks to ensure that, as a whole, it reflects the diversity of our membership and includes the skills, experience, expertise, knowledge, perspectives, education, age, gender, ethnicity, and attributes necessary to effectively oversee the operations and long-term strategy of the HTAi Society. For more information, see the webpage: <https://htai.org/board-of-directors-elections-2022/>.

HTAi provides live webinar series for all HTAi members and potential members. At 7:00 a.m. EST (2:00 p.m. UTC) on February 23, the HTAi Information Retrieval Interest Group hold a webinar on the theme of "Evidence-Based Searching for Health Technology Assessment: Keeping up to Date With SuRe Info ". After that, the theme of the next HTAi webinar was " HTA Informing Innovative Drugs' Market Access in Low- and Middle-Income Countries ", which was held by Developing Countries Interest Group (DCIG) in developing countries. If you miss the live broadcast, all HTAi influential conferences and webcasts,

including webinars, can be found on HTAi's official YouTube channel (website: <https://www.youtube.com/channel/UC9eThoUtBV1omfrkeDcEJPg> ).

The 2022 Global Policy Forum (GPF) was held at Sutton Plaza Hotel, Vancouver, British Columbia, Canada, from March 26 to 28. The theme of this year's global policy forum was " HTA 2025 and Beyond: Data Needs and Uncertainty Management in the Technology Lifecycle".



Key Lab of Health Technology Assessment,  
National Health Commission (Fudan  
University) /  
WHO Collaborating Centre for Health  
Technology Assessment and Management

P.O.Box 197, No 138, Yi Xue Yuan Road,  
Shanghai, 200032  
Tel: 86-21-33565190  
Email: [cwchen@shmu.edu.cn](mailto:cwchen@shmu.edu.cn)  
Website: <https://chta.fudan.edu.cn/>

April 2022 / Issue 1  
Editor: Yuliang Xiang